Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
Gavreto (pralsetinib) is a small molecule inhibitor that selectively targets activated Ret, which may result in antitumor activity including inhibition of tumor growth and tumor regression (PMID: 29657135). Gavreto (pralsetinib) is FDA approved for use in patients with metastatic RET fusion-positive non-small cell lung cancer, in adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer, and in adult and pediatric patients 12 years of age and older with RET fusion-positive thyroid cancer who are radioactive iodine-refractory (FDA.gov).
|DrugClasses||RET Inhibitor 52|
|CAS Registry Number||2097132-94-8|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Afatinib + Pralsetinib||Afatinib Pralsetinib||0||0|
|Crizotinib + Pralsetinib||Crizotinib Pralsetinib||0||0|
|Osimertinib + Pralsetinib||Osimertinib Pralsetinib||0||0|